GSAM
ATRA icon

Grant Street Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Grant Street Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10
Closed -$5K – 202
2020
Q4 		$5K Buy
+10
New +$4.62K ﹤0.01% 192

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Grant Street Asset Management's ATRA Position: Q1 2021 in Review

Grant Street Asset Management sold out of Atara Biotherapeutics (ATRA) in Q1 2021, closing a stake of 10 shares — an estimated $5K sold.

Grant Street Asset Management first reported a position in ATRA in Q4 2020 and held it in 1 quarter. The position peaked at $5K in Q4 2020. 151 funds tracked by Wall St. Rank hold ATRA as of Q1 2021.

  • Grant Street Asset Management reported no remaining Atara Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Grant Street Asset Management sold 10 Atara Biotherapeutics shares in Q1 2021, an estimated $5K.
  • Grant Street Asset Management first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 1 quarter.
  • Grant Street Asset Management's Atara Biotherapeutics position peaked at $5K in Q4 2020.
  • 151 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2021.

Based on Grant Street Asset Management's 13F filing for Q1 2021, filed 4 May 2021.